Trial Search Results
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
To compare the efficacy of TACE vs. CyberKnife SBRT in the treatment of locally recurrent HCC after initial TACE.
1. To determine the progression-free survival of TACE vs. CyberKnife SBRT
2. To determine the overall survival of TACE vs. CyberKnife SBRT for locally recurrent HCC
3. To determine the toxicities associated with TACE or CyberKnife SBRT for the treatment of recurrent HCC.
Stanford is currently not accepting patients for this trial.